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ABSTRACT 
 
Background: Black box warnings indicating harmful or potentially fatal adverse events are required 
by the Food and Drug Administration on certain drugs and chemical entities; however it is unclear if 
prescribing and dispensing habits are impacted by these warnings. This study investigates the 
knowledge and perceptions of prescribers and pharmacists regarding black box warnings. 
Methods: A cross-sectional survey of self-reported behavior related to black box warnings was 
administered to prescribers and pharmacists across North Carolina between October 2010 and 
January 2011. 
Results: A total of 867 pharmacists and prescribers completed the survey, including 715 
pharmacists and 152 prescribers. Of the respondents, 54% were female and 92% described their 
ethnicity as Caucasian. Overall, pharmacists reported a greater change in behavior than did 
prescribers in relation to the presence of a boxed warning (P < .01). Pharmacists also demonstrated 
a significantly greater overall knowledge of boxed warnings compared to prescribers (P < .01).  No 
differences in reported behavior or knowledge were observed between prescribers and pharmacists 
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based on demographic factors.   
Limitations: Solicitation through professional association mailing lists resulting in low response 
rates may impact findings. 
Conclusion: Overall knowledge on information pertaining to boxed warnings was lacking.  Impact in 
clinical practice due to the lack of understanding regarding boxed warnings may put patients at 
increased risk. To improve the overall knowledge of black boxed warnings, the FDA should adopt 
develop a publicly available central repository for all black box warnings. Curricula in schools of 
medicine and pharmacy as well as professional continuing education should include a focus on 
boxed warnings.    
 
 
Keywords: Boxed warning; drug regulation; labeling knowledge; prescribing behavior; dispensing 
behavior.  
 
1. INTRODUCTION 
 
Boxed warnings, frequently called “Black Box 
warnings”, are the strongest warning statements 
that the Food and Drug Administration (FDA) can 
require on a drug label [1]. These cautionary 
statements are placed predominately on the 
package insert and are called boxed warnings 
because of the actual box that surrounds the 
text.  These warnings highlight potentially fatal or 
disabling adverse events that are typically 
identified from clinical data. However in the 
absence of clinical data, serious animal toxicity 
data may be utilized to support this cautionary 
labeling [1].
 
The FDA provides guidance for 
industry in conditions that may warrant a boxed 
warning. These conditions include life 
threatening adverse drug reactions and adverse 
drug reactions that can be prevented or reduced 
in frequency with appropriate drug use and 
monitoring, or with restricted distribution or use 
[2]. However, no clearly defined process or 
criteria exists for applying these standards to 
new drug applications or previously approved 
products [3].  
 
The inclusion of a boxed warning, at approval or 
post-marketing, is designed to make health care 
providers aware of adverse events; however, 
according to the published literature, prescriber 
habits may or may not be affected by boxed 
warning recommendations [4-13]. The post-
marketing addition of boxed warnings for 
antidepressants in pediatric and adolescent 
patients, and the use of antipsychotics in 
dementia patients caused a decline in the use of 
these drug classes for these specific populations 
[7-13]. Although some warnings result in a 
decrease in prescribing habits, residual 
inappropriate prescribing has been documented 
after the addition of some boxed warnings [4-
6,14-16] Lasser et al. [4], reported that 1 in 10 
ambulatory patients was prescribed at least 1 
drug with a boxed warning, with approximately 7 
in 1000 outpatients receiving a prescription for a 
drug that was in violation of the boxed warning.   
It is unclear if prescribers are unaware of the 
boxed warnings associated with these agents or 
utilize clinical judgment to assess a specific 
patient case.  
 
The number of boxed warnings utilized may 
contribute to a lack of knowledge in healthcare 
providers.  According to a historical review of the 
Physician’s Desk References published between 
1975 and 2000, a total of 548 new chemical 
entities were approved. Throughout this time 
period, boxed warnings were added to 45 
chemical entities (8.2%) after initial FDA 
approval [2]. While these data do not include 
boxed warnings that were part of the first 
approved labeling, it does indicate frequent 
addition of new warnings added after widespread 
use.     
 
1.1 Objective 
 
The purpose of this cross-sectional study was to 
examine the health care provider’s knowledge 
and perception of boxed warnings and to 
determine if behavior is affected by these 
warnings. The self-reported awareness, 
perceptions, and impact of boxed warnings on 
prescribing and dispensing habits of providers 
was evaluated via an electronic survey.   
 
2. METHODS 
 
In 2010, a questionnaire (Fig. 1) was distributed 
electronically via Zoomerang to all registered 
pharmacists and prescribers in North Carolina 
(NC) to evaluate the main outcome of self 
reported behavior and knowledge related to 
boxed warnings.  All completed surveys from 
October 26, 2010 to January 1, 2011 were 
utilized in data analysis.  In order to detect at 
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least a 10% difference between groups at 80% 
power with an alpha of .05 a sample of 540 
participants was required. Pharmacist 
participants were recruited by email, via a list 
maintained by the NC Board of Pharmacy, and 
prescriber participants were recruited through a 
postcard delivered by the US postal services. 
The policy of the NC Board of Medicine 
prevented email contact with prescribers, but did 
allow the practice site mailing address to be 
purchased from a public database of all NC 
registered resident prescribers. The post card 
containing a URL linking prescribers to the 
survey was mailed to the address on file with the 
NC Board of Medicine. The post card described 
the study and invited prescribers to participate by 
visiting the link. Prescribers included physicians, 
physician assistants, and nurse practitioners.  
Study participants completed the online survey 
anonymously. Because the NC Board of 
Pharmacy does not disclose individual email 
addresses it was not possible to contact 
pharmacist non-respondents. Similarly, post 
cards sent out to prescribers did not contain a 
unique identifier; therefore, prescriber non-
respondents could not be contacted. The 
decision to exclude an unique identifier was 
made by the research team in order to guarantee 
anonymity of the respondents but also prevented 
any utilization of incentives.  
 
2.1 Data Sources 
 
Several drug information databases were 
queried in June 2010 for drugs containing a 
boxed warning.  These databases included     
Lexi-Comp, Facts and Comparisons, Clinical 
Pharmacology, Micromedex, and 
BlackBoxRX.com.  All commercial products were 
then grouped by active chemical entity.  
Chemical entities no longer available in the 
United States were excluded.  The remaining 
entities were then available for inclusion in the 
survey. 
 
2.2 Ethics Approval 
 
Potential participants who were invited to 
Participate in the study were provided with an 
electronic informed consent statement before the 
start of the survey. The informed consent 
statement indicated that participation in this 
study was completely voluntary and involved 
minimal risk. To access the electronic survey 
respondents were required to read and click 
“agree” to the informed consent document. 
Respondents who clicked “disagree” were 
redirected to a brief message thanking them for 
their time. All authors hereby declare that all 
experiments have been examined and approved 
by the university ethics committee (IRB) and 
have therefore been performed in accordance 
with the ethical standards laid down in the 1964 
Declaration of Helsinki. 
 
2.3 Survey Instrument 
 
The survey questions were developed by the 
research team based on a review of the 
available literature and professional experience 
of the pharmacists conducting the study. 
Questions were reviewed by colleagues for face 
validity, but pretesting was not performed. 
 
The survey collected demographic information 
regarding gender, ethnicity, years in practice, 
and practice type for all participants (Fig. 1). 
Pharmacists responded to a set of questions 
regarding their opinion of the influence which 
boxed warnings have on their practice. 
Prescribers responded to a similar set of 
questions regarding their opinion of the influence 
which boxed warnings have on their practice. All 
participants were asked to indicate how strongly 
they agree with each of three statements 
regarding the number of boxed warnings and the 
number of chemical entities with boxed 
warnings. For each of these statements 
participants could rate their opinion on a 5-point 
Likert scale. The scale consisted of the following: 
“Strongly Agree (5)”, “Agree (4)”, “Neutral (3)”, 
“Disagree (2)”, and “Strongly Disagree (1)”. 
 
Additionally all participants were asked to rate 
their own awareness of boxed warnings using a 
4-point Likert Scale consisting of the following 
options: “Extremely Aware (4)”, “Very Aware (3)”, 
“Somewhat Aware (2)”, and “Not at all Aware 
(1)”. All participants also answered a total of 14 
knowledge questions that related to the actual 
number of chemical entities that possess boxed 
warnings, the type of event that warrants a drug 
or entity to receive a boxed warning, and the 
identification of common drugs that currently 
have a boxed warning. 
 
2.4 Analysis 
 
For behavioral questions related to the influence 
of boxed warnings (Fig. 1). The Likert-scale 
scores for each participant were combined to 
create a composite score ranging between 3 and 
15. The composite score was then compared 
between pharmacists and prescribers using an 
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Fig. 1. Survey instrument 
 
independent samples t-test.  Each participant’s 
knowledge of boxed warnings was evaluated 
through responses to questions in Fig. 1. Overall 
knowledge scores were calculated as the 
percent correct of the knowledge-based 
questions and compared between pharmacists 
 
 
 
 
Demographic information including location of practice (state, county, 
rural or urban), years in practice, gender, and ethnicity. 
Informed Consent 
Profession 
Pharmacists                                                                                Prescribers 
Practice Setting 
(Hospital, Community Pharmacy-Independent, 
Community Pharmacy-Chain, Clinic/Ambulatory Care, 
Industry, Long Term Care, Academia, Other). 
Practice Setting  
(Hospital-Inpatient, Hospital-Emergency Medicine, 
Clinic (ambulatory care, community health center, 
outpatient), Private Practice, Other). 
Behavioral Questions  
5 point Likert Scale-  
Strongly Disagree (1) to Strongly Agree (5) 
1)  I use additional caution when dispensing or 
recommending a drug with a boxed warning. 
2)  I perform a more intense drug utilization review 
when dispensing or recommending a drug with a boxed 
warning. 
  3)  I do not do anything different or additional when 
dispensing or recommending a drug with a boxed 
warning. 
Behavioral Questions  
5 point Likert Scale-  
Strongly Disagree (1) to Strongly Agree (5) 
1)  When I am aware that a drug has a boxed warning 
(“black box” warning), I use additional caution when 
prescribing/using that drug. 
2)  When I am aware, I avoid using drugs with boxed 
warnings (“black box” warnings). 
3)  The fact that a drug has a boxed warning (“black 
box” warning) does not change how I prescribe/use that 
drug. 
Self-Rate Black Box Awareness 
How would you rate your awareness of boxed warnings (“black box warnings”)? 
[Not at all Aware (1), Somewhat Aware (2), Very Aware (3), Extremely Aware (4)] 
Perception of Boxed Warnings 
5 point Likert Scale Strongly Disagree (1) to Strongly Agree (5)-  1)  Too many chemical entities have boxed 
warnings.  2)  An appropriate number of chemical entities have boxed warnings.  3)  Not enough chemical 
entities have boxed warnings. 
Knowledge of Boxed Warnings 
1)  Which of the following would warrant a boxed warning (“black box” warning)? Answer Yes or No for 
each.  A)  Death, B)  Serious Injury, C)  Animal toxicity in the absence of clinical toxicity date,  D)  Side 
effects (serious adverse events) that are present in > 30% of the population,  E)  Unexplained side effects 
(Serious Adverse Events). 
2)  How many chemical entities (active pharmaceutical ingredients) have a boxed warning?  Select one. 
A)  0 to 100, B)  101 to 350, C)  351 to 500, D)  >500. 
3)  Which of the following drugs have a boxed warning?  Answer Yes or No for each. 
A)  Alprazolam (Xanax), B)  Atorvastatin (Lipitor), C)  Fluoxetine (Prozac), D)  Ibuprofen (Motrin), E)  
Lisinopril (Zestril, Prinivil), F)  Nifedipine (Adalat CC, Procardia), G)  Tramadol (Ultram), H)  Warfarin 
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and prescribers using an independent samples t-
test. One-way analysis of variance (ANOVA) was 
used to evaluate differences regarding both 
behavior and knowledge among prescriber 
practice type and among pharmacist practice 
type.  P-values lower than 0.05 were considered 
significant. A reliability analysis was conducted 
for the behavioral questions (see Fig. 1) and a 
Cronbach’s alpha of 0.87 was obtained 
indicating sufficient internal reliability. Descriptive 
statistics are provided for self-reported 
awareness. All analyses were carried out using 
SPSS/PASW 18.0.  This study was approved by 
the Institutional Review Board at Campbell 
University College of Pharmacy & Health 
Sciences.   
 
3. RESULTS 
  
Invitations to participate were mailed to 26,153 
prescribers with 49 post cards returned as 
undeliverable. Invitations to participate were 
emailed to 9,873 pharmacists with 297 returned 
as undeliverable. Of the pharmacists and 
prescribers solicited 1,126 accessed the survey. 
Of those who accessed the survey 77% 
responded to the survey and provided main 
outcome data related to behavior and knowledge 
pertaining to boxed warnings (715 Pharmacists 
and 152 prescribers) (Table 1). For the 867 
respondents 54% were female, 46% were male, 
92% described their ethnicity as Caucasian and 
8% described themselves as non-Caucasian. 
 
3.1 Prescribers and Pharmacists 
 
An independent-samples t test was conducted to 
evaluate the difference in reported behavior 
between prescribers and pharmacists in relation 
to the presence of a boxed warning (Table 2). 
The test was significant, t(865) = 4.65, P < .01. 
Pharmacists on average reported a significantly 
greater change in behavior than did prescribers 
when dealing with products with a boxed warning 
(mean scores, 11.44 versus 10.34, respectively).   
An independent samples t test was conducted to  
 
Table 1. Demographic characteristics 
 
 Pharmacists Prescribers Overall 
Gender [No. (%)] 
   Women 
   Men 
415 (58) 
300 (42) 
50 (33) 
102 (67) 
465 (54) 
402 (46) 
Race [No. (%)] 
   American Indian or Alaskan Native 
   Asian 
   Black or African American 
   Hispanic or Latino 
   Native Hawaiian or Other Pacific 
   Islander 
   White (Caucasian) 
 
7 (1) 
29 (4) 
14 (2) 
0 (0) 
0 (0) 
 
665 (93) 
 
1 (1) 
7 (5) 
10 (7) 
4 (2) 
0 (0) 
 
130 (85) 
 
8 (1) 
36 (4) 
24 (3) 
4 (0) 
0 (0) 
 
795 (92) 
Pharmacist Practice Site [No. (%)] 
   Hospital 
   Community-Independent 
   Community-Chain 
   Clinic/Ambulatory Care 
   Industry 
   Long Term Care 
   Academia 
   Did Not Report 
 
201 (28) 
103 (14) 
202 (28) 
52 (7) 
45 (6) 
26 (4) 
17 (2) 
69 (10) 
  
Prescriber Type [No. (%)] 
   Physician 
   Physician Assistant 
   Nurse Practitioner 
  
117 (77) 
34 (22) 
1 (1) 
 
Prescriber Practice Site [No. (%)] 
   Hospital-Inpatient 
   Hospital-Emergency Medicine 
   Clinic 
   Private Practice 
   Other 
  
23 (15) 
12 (8) 
38 (25) 
61 (40) 
18 (12) 
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Table 2. Behavioral and perception questions mean scores 
 
 Pharmacists 
Mean ± SD  
(# of respondents) 
Prescribers 
Mean ± SD  
(# of respondents) 
P-value 
How many years have you been in practice? 18.99 ± 13.27 (715) 20.31 ± 11.69 (152) .26 
Additional caution is used when dispensing/recommending/prescribing a drug with a 
boxed warning.
a
 
3.95 ± .89 (715) 4.24  ± .81 (152) < .01 
I perform a more intense drug utilization review when dispensing or recommending a 
drug with a boxed warning.
a
  
3.76 ± .94 (715) N/A N/A 
When I am aware, I avoid using drugs with boxed warnings (“black box” warnings).a N/A 2.66  ± 1.14 (152) N/A 
I do not do anything different or additional when dispensing/ 
recommending/prescribing a drug with a boxed warning.
a
  
3.79 ± 1.07 (715) 3.43  ± 1.14 (152) <.01 
Combined Score for Behavioral Questions 11.44 ± 2.67 (715) 10.34  ± 2.49 (152) < .01 
How would you rate your awareness of boxed warnings ("black box warnings")?
b
 2.62 ± .64 (670) 2.63  ± .67 (144) .81 
Too many chemical entities have boxed warnings.a  3.18 ± .97 (670) 3.15  ± 1.05 (144) .78 
An appropriate number of chemical entities have boxed warnings.
a
 2.98 ± .87 (670) 2.94  ± .83 (144) .69 
Not enough chemical entities have boxed warnings.
a
  2.54 ± .85 (670) 2.58  ± .90 (144) .55 
Note: a. Responses,5-point Likert Scale; b. Responses, 4-point Likert Scale, N/A = Not Applicable 
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evaluate the difference in overall mean score      
for knowledge between pharmacists and 
prescribers. Pharmacists demonstrated a 
significantly greater overall knowledge [t(868) = 
3.18, P < .01] of boxed warnings than did 
prescribers (Table 3). 
 
No differences in either reported behavior or 
knowledge were observed between prescribers 
and pharmacists based on demographic factors 
such as gender, ethnicity (white versus non-
white), or location. 
 
3.2 Among Prescribers 
 
A one-way ANOVA was conducted to evaluate 
the relationship between reported behavior 
related to boxed warnings and practice type of 
prescribers. The independent variable, practice 
type, consisted of four levels: Hospital – 
Inpatient, Hospital – Emergency Medicine, Clinic, 
and Private Practice. The dependent variable 
was the composite score of reported behavior 
related to boxed warnings. The ANOVA was 
significant, F(3, 130) = 2.977, P = .03. 
 
Pair-wise comparisons demonstrated the 
differences among the means. Tukey post-hoc 
analysis confirmed that prescribers who 
indicated their practice type to be Hospital – 
Emergency Medicine had a higher overall 
composite score related to behavior than all 
other practice types included in the study.  The 
95% confidence intervals as well as the means 
and standard deviations for the practice types 
are reported in Table 4. 
 
A one-way ANOVA was conducted to evaluate 
the relationship between knowledge of boxed 
warnings and practice type of prescribers. The 
independent variable, practice type, consisted of 
four levels: Hospital – Inpatient, Hospital – 
Emergency Medicine, Clinic, and Private 
Practice. The dependent variable was the 
composite score for knowledge of boxed 
warnings. The ANOVA was not significant.  No 
differences were observed regarding reported 
behavior and demographic factors such as 
ethnicity or gender. 
 
3.3 Among Pharmacists 
 
A one-way ANOVA was conducted to evaluate 
the relationship between reported behavior 
related to boxed warnings and practice type of 
pharmacists. The independent variable, practice 
type, consisted of seven levels: Academia, 
Community Pharmacy – Independent, 
Community Pharmacy – Chain, Hospital, 
Clinic/Ambulatory Care, Long Term Care, 
Industry. The dependent variable was the 
composite score of reported behavior related to 
boxed warnings. The ANOVA was not 
significant.  
 
A one-way ANOVA was conducted to evaluate 
the relationship between knowledge of boxed 
warnings and practice type of pharmacists. The 
independent variable, practice type, consisted of 
seven levels: Academia, Community Pharmacy–
Independent, Community Pharmacy – Chain, 
Hospital, Clinic/Ambulatory Care, Long Term 
Care, Industry. The dependent variable was the 
composite score for the knowledge questions. 
The ANOVA was not significant.  No differences 
were observed regarding reported behavior and 
demographic factors such as ethnicity or gender. 
 
4. DISCUSSION 
 
Overall, knowledge of the justification and 
requirements for a boxed warning, number of 
chemical entities with a boxed warning, and 
individual agents that have a boxed warning was 
lacking. On the knowledge-based questions, 
prescribers scored on average 56% while 
pharmacists scored on average 59%, indicating 
a gap in knowledge for both groups.   
 
An incomplete understanding of criteria for the 
addition of a boxed warning to a chemical entity 
related to significant animal toxicity, even in the 
absence of human data, existed.  Only 16% of 
survey respondents identified the animal toxicity 
as appropriate criteria for a boxed warning.  
However, the recent approval of liraglutide 
(Victoza – Novo Nordisk A/S) included a boxed 
warning for increased risk of thyroid C-Cell 
tumors that has only been observed in rodents 
[17]. The human risk, although the extent is 
currently unknown, was significant enough to 
warrant this labeling.  
 
Wang et al. [18] evaluated the consistency of 3 
commonly used databases in detecting an 
interaction in drugs contraindicated to be used 
concurrently.  Each of the 3 interaction screening 
databases reported less than half of the 
expected interactions.  The authors noted that 
the information regarding severity and evidence 
for contraindicated drug combinations, 
specifically addressed in boxed warnings, is 
quite variable between databases.  
Inconsistencies between databases and product 
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package inserts have also been documented 
[19]. These inconsistencies may contribute to 
lack of knowledge since many prescribers or 
pharmacists typically have access to only one or 
two databases in daily practice.  A contributor to 
this problem may be related to the lack of a FDA 
maintained list of all drugs/entities with a boxed 
warning. 
 
The two drugs in our survey that were most 
frequently correctly identified by prescribers as 
having a boxed warning were warfarin and 
fluoxetine (78% and 74%, respectively; Table 3).  
One reason for increased awareness for 
fluoxetine may be related to the intense lay 
media coverage of the announcement by the 
FDA to include a boxed warning due to the 
increased potential of suicide in children and 
adolescents on all antidepressants [20].  While 
lay media coverage of boxed warnings may be 
an avenue to communicate the risks, one study 
indicates that FDA  and lay media reports of 
boxed warnings emphasized different 
information that is thought to be related to the 
different reasons for reporting the information 
[21]. These differences identified included an 
under reporting in the lay media of the       
generic names, research methods, clinical 
recommendations, and instruction to seek health 
care provider advice and an increased reliance 
on expert testimonials and personal stories from 
patients [21].  A similar effect attributed to the lay 
press was documented in Moeller et al. [22] for 
paroxetine and estrogen.  
 
Table 3. Knowledge results 
 
 Pharmacists 
no. (%) 
Prescribers 
no. (%) 
P-value 
Which of the following would warrant a  
boxed warning (“black box” warning)? 
--Death a 623 (93) 134 (93)  
--Serious Injury
 a
 619 (92) 125 (87)  
--Animal toxicity in absence of clinical toxicity data a 104 (15) 25 (17)  
--Side Effects (Serious Adverse Events) that are 
present in >30% of the population 
410 (61) 96 (67)  
--Unexplained side effects (Serious Adverse Events) 304 (45) 73 (51)  
How many chemical entities (active 
 pharmaceutical ingredients) have boxed warnings 
 (“black box” warnings)? 
0 to 100 271 (40) 37 (25)  
101 to 350 256 (38) 67 (47)  
351 to 500 a 96 (14) 22 (15)  
>500 48 (7) 18 (12)  
Which of the following drugs have a boxed warning 
(“black box” warning)? 
Alprazolam (Xanax-Pfizer US Pharmaceutical Group) 107 (16) 42 (29)  
Atorvastatin (Lipitor-Pfizer US Pharmaceutical Group) 237 (35) 49 (34)  
Fluoxetine (Prozac-Eli Lilly & Co.) a 536 (80) 107 (74)  
Ibuprofen (Motrin)
 a
 285 (42) 51 (35)  
Lisinopril (Zestril-AstraZeneca, Prinivil-Merck Sharp & 
Dohme)
 a
 
218 (32) 58 (40)  
Nifedipine (Adalat CC-Schering-Plough Corporation, 
Procardia-Pfizer US Pharmaceutical Group) 
151 (23) 43 (30)  
Tramadol (Ultram-Janssen) 210 (31) 62 (43)  
Warfarin (Coumadin-Bristol-Myers Squibb Company)
 a
 598 (89) 113 (78)  
Overall Mean Percent Score ± SD 59 ± 13 56 ± 15 < .01 
Total Complete Respondents 671 (82) 144 (18)  
a Correct answer 
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Table 4. Comparison of mean composite scores for reported behavior of prescribers by 
practice type 
 
Practice type M SD Mean Diff.  
(Hospital-Emergency) 
95% CI for Diff. of Means 
Hospital-Emergency 12.42 2.43   
Hospital-Inpatient 10.09 2.25 2.33
a
 .02-4.64 
Clinic 10.24 2.67 2.18a .03-4.33 
Private Practice 10.16 2.47 2.26
a
 .21-4.30 
Note: 
a
P < .05 
The effect caused by the existence of a boxed 
warning is mixed.  In a study conducted by 
Lasser et al. [4], 7 out of 1000 outpatients 
received a prescription drug in violation of a 
boxed warning.  However, an even higher rate of 
non-compliance with boxed warnings has been 
documented [14,16,23,24]. Of particular note are 
studies that examine the contraindicated use of 
metformin in patients with heart failure and/or 
renal failure due to the increased risk of lactic 
acidosis in this population [14,25,26].  Another 
area of documented non-compliance with a 
boxed warning occurred in the monitoring of 
patients taking lithium, carbamazepine, and 
valproate [27]. However, the rate of 
antidepressant use in children did diminish after 
the addition of a boxed warning to this class of 
drugs [13]. Also, changes to the use of 
antipsychotics in patients with dementia 
decreased after the addition of a boxed warning 
[10]. The reasons for non-compliance to a boxed 
warning or the absence of change in usage after 
the addition of a boxed warning are not known.  
Our data indicate that there may be a lack of 
knowledge of which agents have a particular 
type of boxed warning and this may be related to 
the large number of agents that include such a 
warning and database inconsistencies. These 
results suggest a need for additional black box 
education in schools of medicine and pharmacy 
in addition to professional continuing education 
focused on boxed warnings.  Another effort to 
improve the overall knowledge of boxed 
warnings would be one central repository for all 
agents with boxed warnings. Consideration 
should be given to prominence and consistency 
of black box warning placement on literature 
provided with all medications prescribed to 
patients with additional information provided to 
prescribers that describe the evidence base 
which led to the boxed warning in the first place. 
If prescribers and patients are able to 
consistently find and review these warnings then 
prescribers may consider alternative medications 
in some instances. At the very least providing the 
evidence base will allow prescribers to consider 
appropriate prescribing in context of the 
individual patient.   
 
5. LIMITATIONS 
 
The study is limited by the sample surveyed.  
Only prescribers and pharmacists in NC were 
recruited to participate. The inability to gain 
direct access to respondent names and email 
addresses prevented effective follow up for the 
majority of the population solicited; therefore, a 
follow up request and an evaluation of non-
responders was not possible. The inclusion of a 
web link in the email solicitation to pharmacists 
likely contributed to the stark contrast in 
response rates (715 pharmacists vs. 152 
prescribers). The extra step required for 
prescribers to respond consisted of typing in a 
web link from the post cards perhaps inhibiting 
response rates in this group. Additionally, since 
the respondents were utilizing the internet to 
complete the survey, references could have 
been used to assist with the completion of the 
knowledge based questions.  This could over-
estimate the mean knowledge scores of 
participants.  This study utilized self-reported 
data, which may not translate into actual practice 
behaviors.  Formal pretesting was not performed 
on the survey tool.  The actual wording of survey 
questions between prescribers and pharmacists 
differed slightly, which may contribute to some of 
the differences observed. Lastly, the small 
proportion of prescriber respondents limits the 
power of the analysis – particularly for sub-group 
analysis.    
 
6. CONCLUSION 
 
Knowledge on justification and requirements for 
a boxed warning, number of chemical entities 
with a boxed warning, and individual agents that 
have a boxed warning was deficient with a mean 
score less than 60%. Low overall knowledge 
may indicate a barrier to communicating the 
purpose and reasoning for the addition of a 
boxed warning to a drug label. Impact in clinical 
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practice due to the lack of understanding 
surrounding boxed warnings may put patients at 
an increased risk for serious adverse reactions. 
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